ReviewVascular health and risk management2020

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.

George G Sokos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.